Drug Trial Radar · NCT06735820
Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST
Last checked: Nov 19, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Oct 1, 2027
Study completion Oct 1, 2028
Sponsor
- Lead sponsor
- AeRang KimAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Children's National Research Institute
- First posted
- Dec 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 0/1/2, multi-site study to evaluate the MEK inhibitor Selumetinib with the MDM2 Inhibitor APG-115 in patients with Neurofibromatosis Type 1 and pre-malignant and malignant peripheral nerve sheath tumors
Conditions
- Malignant Peripheral Nerve Sheath Tumor (MPNST)
- Neurofibromatosis 1 (NF1)
- Atypical Neurofibroma
Interventions
APG-115Drug
Combination therapy of APG-115 and Selumetinib
SelumetinibDrug
Combination therapy of APG-115 and Selumetinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of treated patients with adverse events as determined by the common criteria for adverse version 5 (CTCAEv5).Time frame: 15 months
- Tumor response by imaging using RECISTv1.1Time frame: 28 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Children's National Hospital
Washington D.C., District of Columbia · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.